PERFORMANCE · Injectable

GHRP-6.

Ghrelin receptor agonist — GH pulse amplification

How it works

Class & mechanism.

In short

GHRP-6 is a research peptide that activates the ghrelin receptor to trigger pulses of growth hormone release and stimulate appetite. It has historically been studied alongside GHRH analogues for GH support and, separately, for cachexia and wasting conditions. GHRP-6 is currently on the FDA's Category 2 do-not-compound list, so this content is provided for educational context only.

Class

Growth Hormone Releasing Peptide (GHRP)

Mechanism

GHRP-6 (Growth Hormone Releasing Peptide-6) is a 6-amino acid synthetic peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) that acts as a potent ghrelin receptor (GHS-R1a) agonist. It stimulates the pituitary gland to release growth hormone (GH) through a different pathway than GHRH analogues like CJC-1295 — GHRP-6 acts directly on the ghrelin receptor to amplify the natural GH pulse amplitude rather than extending its duration. This makes it complementary to GHRH analogues. It also stimulates appetite via the ghrelin pathway, which distinguishes it from more selective GHRPs like Ipamorelin.

Personalized Peptides provides DNA-driven peptide recommendations — we are not a compounding pharmacy, peptide synthesis company, or clinical provider.

Did you know

GHRP-6 is the appetite-stimulating sibling in the GHRP family — unlike Ipamorelin (which leaves hunger alone), GHRP-6 makes you hungry by design. This was actually the original research purpose: ghrelin receptor agonists were studied for cachexia and wasting before bodybuilders discovered the GH benefit.

Preclinical Data

No human PK studies available.

Human PK characterised in small clinical studies — t½ ~45-55 min SC, limited cohort sizes

Class

Synthetic ghrelin receptor (GHS-R1a) agonist — hexapeptide

Route

SC / IM

Mol. Weight

873 Da

What we don't know

Human PK from small clinical pharmacology studies (n=6-12) established SC t½ ~45-55 min, Tmax ~15-30 min, and dose-proportional GH release up to ~300mcg. Bioavailability ~85-90% SC. However, larger PK studies and long-term safety data are absent. GHRP-6 has been largely superseded by ipamorelin in clinical wellness protocols due to GHRP-6's pronounced appetite stimulation and cortisol/prolactin elevation at higher doses.

Why this dosing protocol

Standard protocol mirrors other GH secretagogues: 100-300mcg SC 1-3× daily, always fasted. The combination with CJC-1295 (no-DAC) at 100mcg each produces a synergistic GH pulse greater than either alone. Appetite stimulation is dose-dependent — users sensitive to this effect dose at 100mcg; users seeking the orexigenic effect for bulking protocols dose at 200-300mcg pre-meal. Evening dosing may disrupt sleep due to cortisol elevation.

Empirical protocol: 100-300mcg SC 1-3× daily, fasted

Safety notes

  • Appetite stimulation (desired or undesired)
  • Cortisol/prolactin elevation at higher doses
  • Limited long-term human data

Pharmacokinetic data shown for educational context. All parameters are inferred or empirically derived — no formal human PK studies exist for this compound. Individual response varies. Not a substitute for clinical dosing guidance.

Benefits

What it does.

01

Growth hormone pulse amplification — directly stimulates pituitary GH release via ghrelin receptor agonism

02

Complementary to GHRH analogues — pairs well with CJC-1295 for synergistic GH elevation (amplitude + duration)

03

Appetite stimulation — ghrelin receptor activation increases hunger, which can benefit individuals struggling to eat enough for muscle growth

04

Recovery and healing — elevated GH supports tissue repair, collagen synthesis, and post-exercise recovery

The science

Peer-reviewed findings.

Research supporting this compound's mechanisms and safety profile.

What this does not mean

GHRP-6 remains on FDA Category 2 (do not compound list). The information on this page is educational and does not constitute medical advice, diagnosis, or treatment, and nothing here should be read as an endorsement of current compounding, sourcing, or human use of GHRP-6. GHRP-6 is not FDA-approved for any indication. This page does not recommend, endorse, or prescribe any compound for human use. Always consult a qualified healthcare provider before making health decisions. Personalized Peptides provides DNA-driven educational context and test interpretation — not clinical protocols, sourcing guidance, or pharmaceutical recommendations.

GHRP-6

GHRP-6 is one of the most studied GHRPs with extensive preclinical and clinical data on its GH-releasing effects; dose-dependent GH elevation demonstrated across multiple human studies

SOURCE · Multiple peer-reviewed publications; ghrelin receptor pharmacology literature

Protocol

How to use it.

Dosing

100–300 mcg subcutaneous injection, 1–3× per day. Typically administered 30 minutes before meals or before bed to coincide with natural GH pulses.

Cycle

8–12 week cycles typical. Many protocols use 5 days on / 2 days off to manage receptor desensitization. The appetite-stimulating effect diminishes over time as tolerance develops.

Contraindications

When to skip it.

Appetite stimulation can be problematic for weight management. Cortisol and prolactin elevation at higher doses (less selective than Ipamorelin). Banned by WADA for competitive athletes. Use under physician supervision.

Always cleared with your concierge before protocol start.

Regulatory Context

FDA compounding status.

FDA StatusRisk LevelCompoundingKey Date
Category 2 — Do Not Compound🔴 At RiskNot eligible — remains on Category 2No PCAC date announced

Moved to Category 2 in late 2023. NOT among the 12 peptides removed Apr 23, 2026. Not on either PCAC agenda. Remains prohibited for compounding. Ghrelin receptor agonist.

Source: FDA Federal Register, PCAC agendas, industry analyses. Educational context only — not legal advice. Review after July 23-24, 2026 PCAC meeting.

Pricing

What it costs.

Indicative range for GHRP-6, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.

Indicative range (USD)

per cycle

Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.

  • 0199% purity verified, third-party tested
  • 02Includes vial and reconstitution guidance
  • 03Concierge supplier match included with every protocol
Sign in to unlock

See GHRP-6 pricing — and your supplier match.

Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.

  • Live USD price range
  • US & EU supplier shortlist
  • Concierge sign-off on dosing

Indicative price range: $90–$134 USD